Fund Details
Overview
Investment portfolio
16rounds
| NAME | DATE | SIZE | |
|---|---|---|---|
Kainova Therapeutics | Feb 2026Participated | $24 MSeries B | |
OutSee | Jun 2025Participated | $2 MSeed | |
Human Longevity | Aug 2024Participated | $40 MSeries B | |
Actym Therapeutics, Inc. | Oct 2023Participated | $60 MSeries A | |
hC Bioscience | Nov 2022Participated | $16 MSeries A | |
HanchorBio | Aug 2022Participated | $20 MSeries A | |
Domain Therapeutics | May 2022Led | $41 MSeries A | |
Day Zero Diagnostics | Feb 2022Participated | $21 MOther Equity | |
Inmagene Biopharmaceuticals | Jun 2021Led | $100 MSeries C | |
Chime Biologics | Mar 2021Participated | $190 MSeries A | |
Inmagene Biopharmaceuticals | Nov 2020Participated | $21 MSeries B | |
Zhaoke Ophthalmology Pharmaceutical | Oct 2020Participated | $145 MSeries B | |
Kainova Therapeutics | Feb 2026Participated | $24 MSeries B | |
OutSee | Jun 2025Participated | $2 MSeed | |
Human Longevity | Aug 2024Participated | $40 MSeries B | |
Actym Therapeutics, Inc. | Oct 2023Participated | $60 MSeries A | |
hC Bioscience | Nov 2022Participated | $16 MSeries A | |
HanchorBio | Aug 2022Participated | $20 MSeries A | |
Domain Therapeutics | May 2022Led | $41 MSeries A | |
Day Zero Diagnostics | Feb 2022Participated | $21 MOther Equity | |
Inmagene Biopharmaceuticals | Jun 2021Led | $100 MSeries C | |
Chime Biologics | Mar 2021Participated | $190 MSeries A | |
Inmagene Biopharmaceuticals | Nov 2020Participated | $21 MSeries B | |
Zhaoke Ophthalmology Pharmaceutical | Oct 2020Participated | $145 MSeries B |
16 Items
16
Items
...
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 0 | 1 |
| Series A | 2 | 4 |
| Series B | 0 | 6 |
| Series C+ | 2 | 0 |
| Other Equity | 0 | 1 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Sep '18 | 1 |
| Oct '18 | 0 |
| Nov '18 | 0 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 0 |
| Mar '19 | 0 |
| Apr '19 | 0 |
| May '19 | 0 |
| Jun '19 | 1 |
| Jul '19 | 0 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 1 |
| May '20 | 0 |
| Jun '20 | 0 |
| Jul '20 | 0 |
| Aug '20 | 0 |
| Sep '20 | 1 |
| Oct '20 | 1 |
| Nov '20 | 1 |
| Dec '20 | 0 |
| Jan '21 | 0 |
| Feb '21 | 0 |
| Mar '21 | 1 |
| Apr '21 | 0 |
| May '21 | 0 |
| Jun '21 | 1 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 1 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 1 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 1 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 1 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 1 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 1 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 1 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 1 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 16 |
| Marketing & Advertising | 1 |
| Manufacturing | 1 |
| Space & Frontier Tech | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 1 |
| $5M-$10M | 0 |
| $10M-$25M | 5 |
| $25M-$50M | 5 |
| $50M-$100M | 2 |
| $100M-$250M | 3 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 5 of 5 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 8 |
| Europe | 4 |
| China | 2 |
| Taiwan | 1 |
| Hong Kong | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| 3B Future Health Fund | 2 |
| adMare BioInnovations | 2 |
| Boehringer Ingelheim | 2 |
| CTI Life Sciences Fund | 2 |
| Illumina Ventures | 2 |
| JLo Ventures | 2 |
| Korea Investment Partners | 2 |
| Schroders Capital | 2 |
| Seventure Partners | 2 |
| Turenne Capital | 2 |
| Viva BioInnovator | 2 |
| 8VC | 1 |
| Ahren Innovation Capital | 1 |
| ARCH Venture Partners | 1 |
| BD | 1 |
| Borealis Ventures | 1 |
| Cowen Healthcare Investments | 1 |
| Coyote Ventures | 1 |
| Emerging Technology Partners | 1 |
| Empirical Ventures | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 4 | 25% |
| Participating | 12 | 75% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 2 | 50% |
| Co-led | 2 | 50% |
Team
Debra Yu
Partner and COO